Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6Stomach Neoplasms 5Esophageal Neoplasms 3Colorectal Neoplasms 3Biliary Tract Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Salivary Gland Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Metastatic HER2-positive Breast Cancer 1HER2-expressing Cancers 1HER2-Positive Advanced Biliary Tract Cancer 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Advanced Malignancies 1

Interventions

zanidatamab 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER2-expressing Cancers × zanidatamab × Clear all
NCT05027139 2025-10-16

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Jazz Pharmaceuticals

Phase 1/2 Completed
52 enrolled

HER2-expressing Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡